查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086212

陣發性睡眠性血尿症治療市場：依治療分類、給藥途徑、治療階段、劑量模式、最終用途及通路分類－2026-2032年全球市場預測

Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Treatment Class, Route of Administration, Line of Therapy, Dosing Pattern, End Use, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，陣發性睡眠性血尿症的治療市場將成長至 100.7 億美元，複合年成長率為 9.34%。

主要市場統計數據
基準年 2025 53.9億美元
預計年份：2026年 58.8億美元
預測年份 2032 100.7億美元
複合年成長率 (%) 9.34%

陣發性睡眠性血尿症)的治療已從症狀治療轉變為精準的補體抑制，徹底改變了這種罕見後天性造血幹細胞疾病患者的治療結果。 PNH 的特徵是補體依賴性溶血、貧血、血栓症形成風險增加、疲勞、腎臟併發症和生活品質下降。通常透過高靈敏度的流式細胞技術確診，此方法可檢測血球上糖基磷脂醯肌醇 (GPI) 錨定蛋白的缺陷。

治療的基礎是成熟的補體療法，包括C5抑制劑（如Eculizumab和拉維珠單抗）、近端補體抑制劑（如培塞他考普蘭）、口服B因子抑制劑（如伊普他考泮），以及對於接受C5阻斷治療且出現臨床顯著血管外溶血的患者，額外使用D因子抑制劑（如達尼考泮）。這些進展已將治療競爭的重點從單純抑制溶血擴展到使血紅蛋白正常化、避免輸血、給藥方便、預防突發性溶血、提高患者用藥依從性以及確保長期安全性。

PNH治療格局的變革性變化

陣發性睡眠性血尿症(PNH) 治療領域最顯著的變化在於，治療策略從傳統的末端補體抑制療法轉向更廣泛的、同時靶向末端和近端補體途徑的治療方案。雖然 C5 抑制劑仍然是降低血管內溶血和血栓形成風險的臨床成熟療法，但針對 C3、因子 B 和因子 D 的療法可以解決殘餘疾病活動，包括某些患者因血管外溶血引起的貧血。

人工智慧對發性睡眠性血紅蛋白尿症 (PNH) 護理的累積影響

人工智慧 (AI) 正透過改善罕見疾病的識別、將患者與臨床試驗配對、分析實驗室數據以及上市後監測，開始影響早發性神經病變 (PNH) 的治療生態系統。由於 PNH 的症狀與再生障礙性貧血、骨髓發育不良症候群、自體免疫溶血和不明原因血栓症的症狀重疊，AI 驅動的電子健康記錄篩檢可以識別出具有持續溶血、血細胞減少、乳酸脫氫酵素(LDH) 水平升高、血栓症病史和輸血依賴等特徵的患者，從而使他們能夠被轉診給專科醫生進行進一步評估。

主要區域洞察：北美、歐洲、亞太、拉丁美洲、中東和非洲

由於監管措施實施較早、專科醫生密度高、保險報銷途徑完善以及積極參與罕見疾病臨床試驗，北美仍然是陣發性睡眠性血尿症治療的主要地區。雖然美國是補體抑制劑的主要上市市場，但加拿大的藥物准入環境受到醫療技術評估、省級保險報銷決策以及高成本藥物的證據要求等因素的影響。

主要集團洞察：七國集團、歐盟、金磚國家、東協、海灣合作理事會、北約

七國集團（G7）擁有先進的監管機構、完善的罕見疾病框架、廣泛的血液學專業知識以及強大的高成本生物製藥和創新口服療法的資金支持，共同構成了陣發性睡眠性血紅蛋白尿症（PNH）治療領域商業性化程度最高的環境。即使在七國集團內部，市場准入也因支付模式的差異而有所差異。美國強調私人和公共保險覆蓋範圍的趨勢，而歐洲成員國則依賴國家層面的估值和價格談判。

主要 PNH 治療市場的關鍵國家洞察

美國得益於FDA的孤兒藥核准流程、主要的學術血液疾病中心以及已通過核准的補體抑制劑的快速應用，已成為陣發性睡眠性血紅素尿症（PNH）治療領域創新和商業化的重要中心。加拿大則採用更集中的證據審查和省級報銷模式。在墨西哥和巴西，儘管對罕見疾病治療的需求日益成長，但獲得治療的機會往往取決於公共醫療保險的覆蓋範圍、訴訟程序、私人保險以及專科醫療中心的可用性。

針對陣發性夜間血紅蛋白尿症（PNH）治療領域領導者的實用建議

產業領導者應優先考慮差異化證據，這些證據能夠反映血液科醫生和保險公司如何評估最新的陣發性睡眠性血紅蛋白尿症 (PNH) 療法。具體而言，這包括持續的溶血控制、血紅蛋白水平的提高、無需輸血、突破性溶血的減少、患者自述疲勞的改善、安全性以及用藥依從性。隨著多種針對 C5、C3、因子 B 和因子 D 機制的療法相互競爭，來自直接比較試驗和真實世界數據的證據的重要性只會與日俱增。

旨在深入了解檢驗性血紅蛋白尿症 (PNH) 治療方案的調查方法

本執行摘要基於系統性的二手研究方法，採用檢驗資訊來源，例如來自權威藥品監管機構的批准和處方資訊、同行評審的血液學文獻、臨床指南、臨床試驗論文、罕見疾病登記資料以及醫療技術評估調查方法。本分析著重於檢驗的臨床和監管事實，而非缺乏依據的市場預測。

結論：PNH治療的未來

陣發性睡眠性血尿症(PNH) 的治療格局正朝著更具競爭性和以患者為中心的方向發展。雖然現有的 C5 抑制劑仍發揮核心作用，但近端補體抑制劑和口服療法正在拓展最佳疾病控制的定義。支付方對治療的便利性、堅持性、殘餘貧血的管理、真實世界療效和長期價值的信心，日益影響著這一治療格局。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：陣發性睡眠性血尿症的治療市場：依治療分類

  • 補體抑制劑
    • Eculizumab
    • 洛維茲瑪
  • 治療方法
  • 支持性和預防性護理
    • 輸血
    • 鐵螯合療法
    • 抗凝血治療
    • 鐵和葉酸補充療法

第8章：陣發性睡眠性血尿症的治療市場：依給藥途徑分類

  • 靜脈
  • 皮下
  • 口服

第9章：陣發性睡眠性血尿症治療市場：依治療階段分類

  • 第 1 行
  • 第二行
  • 第三行

第10章：陣發性睡眠性血尿症的治療市場：依劑量模式分類

  • 依標準間隔進行腸外給藥
  • 延長給藥間隔的腸外給藥
  • 每日一次口服維持治療

第11章：陣發性睡眠性血尿症治療市場：依最終用途分類

  • 醫院
  • 專科診所/血液疾病中心
  • 居家照護環境

第12章：陣發性睡眠性血尿症治療市場：依通路分類

  • 離線
  • 線上

第13章：陣發性睡眠性血尿症治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：陣發性睡眠性血尿症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：陣發性睡眠性血尿症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AstraZeneca PLC
  • Alnylam Pharmaceuticals, Inc.
  • Samsung Bioepis Co., Ltd.
  • Novo Nordisk A/S
  • Apellis Pharmaceuticals, Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Akari Therapeutics, Plc
  • Amgen Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Kira Pharmaceuticals, Inc.
  • NovelMed Therapeutics, Inc.
  • Sanofi SA
  • Swedish Orphan Biovitrum AB
Product Code: MRR-036C5CF3B54F

The Paroxysmal Nocturnal Hemoglobinuria Treatment Market is projected to grow by USD 10.07 billion at a CAGR of 9.34% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.39 billion
Estimated Year [2026] USD 5.88 billion
Forecast Year [2032] USD 10.07 billion
CAGR (%) 9.34%

Paroxysmal nocturnal hemoglobinuria treatment has moved from supportive care to precision complement inhibition, reshaping outcomes for patients with this rare, acquired hematopoietic stem cell disorder. PNH is characterized by complement-mediated hemolysis, anemia, thrombosis risk, fatigue, kidney complications, and impaired quality of life, with diagnosis typically confirmed by high-sensitivity flow cytometry detecting glycosylphosphatidylinositol-anchored protein deficiencies on blood cells.

The treatment landscape is anchored by proven complement therapies, including C5 inhibitors such as eculizumab and ravulizumab, proximal complement inhibitors such as pegcetacoplan, oral factor B inhibition with iptacopan, and add-on factor D inhibition with danicopan for clinically significant extravascular hemolysis in patients receiving C5 blockade. These advances are expanding the competitive focus from hemolysis control alone to hemoglobin normalization, transfusion avoidance, dosing convenience, breakthrough hemolysis prevention, patient adherence, and long-term safety.

Transformative Shifts in the PNH Treatment Landscape

The most important shift in paroxysmal nocturnal hemoglobinuria treatment is the transition from terminal complement blockade as the dominant standard to a broader portfolio that targets both terminal and proximal complement pathways. C5 inhibition remains clinically established for reducing intravascular hemolysis and thrombotic risk, while C3, factor B, and factor D approaches address residual disease activity, including anemia driven by extravascular hemolysis in selected patients.

Competition is also shifting around route of administration and treatment burden. Long-acting intravenous dosing, self-administered subcutaneous options, and oral therapies are redefining patient preference, clinic capacity, payer evaluation, and real-world adherence. As more agents gain regulatory acceptance, stakeholders must differentiate on durable lactate dehydrogenase control, hemoglobin improvement, transfusion independence, safety monitoring, vaccination requirements, and evidence in treatment-naive versus previously treated populations.

Cumulative Impact of Artificial Intelligence on PNH Care

Artificial intelligence is beginning to influence the PNH treatment ecosystem by improving rare disease identification, clinical trial matching, laboratory analytics, and post-market surveillance. Because PNH symptoms overlap with aplastic anemia, myelodysplastic syndromes, autoimmune hemolysis, and unexplained thrombosis, AI-enabled screening of electronic health records can help flag patients with patterns such as persistent hemolysis, cytopenias, elevated lactate dehydrogenase, thrombosis history, and transfusion dependence for specialist review.

The cumulative impact of AI is expected to be strongest where data quality is high and clinical validation is rigorous. Machine learning can support flow cytometry quality control, predict breakthrough hemolysis risk, identify adherence gaps, optimize site selection for rare disease trials, and strengthen pharmacovigilance by detecting safety signals across registries, claims, and spontaneous reporting systems. However, AI should be deployed as decision support rather than autonomous diagnosis, with transparent algorithms, bias testing, clinician oversight, and compliance with health data privacy regulations.

Key Regional Insights: North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa

North America remains a leading region for paroxysmal nocturnal hemoglobinuria treatment because of early regulatory adoption, high specialist density, established reimbursement pathways, and strong participation in rare disease clinical trials. The United States has been a major launch market for complement inhibitors, while Canada's access environment is shaped by health technology assessment, provincial reimbursement decisions, and evidence requirements for high-cost medicines.

Europe benefits from centralized European Medicines Agency review, national reimbursement systems, and mature hematology networks across major markets. The European Union's rare disease policy framework and orphan drug incentives support innovation, but country-level pricing negotiations can create staggered access. The United Kingdom, Germany, France, Italy, and Spain remain important markets due to advanced diagnostic capacity, specialist care pathways, and structured assessment of clinical value, safety, and budget impact.

Asia-Pacific is gaining strategic importance as Japan, China, South Korea, Australia, and India expand rare disease awareness, diagnostic infrastructure, and access to advanced biologics and oral therapies. Latin America shows growing need but uneven access, with Brazil and Mexico representing key markets where reimbursement, affordability, and tertiary-center capacity influence adoption. The Middle East, led by Gulf health systems, is investing in specialty care, rare disease programs, and advanced hospital infrastructure, while Africa faces the largest gaps in diagnosis, reimbursement, laboratory capacity, and availability of complement-targeted therapies.

Key Group Insights: G7, EU, BRICS, ASEAN, GCC, and NATO

The G7 countries collectively represent the most commercially mature environment for PNH treatment, supported by advanced regulatory agencies, established rare disease frameworks, broad hematology expertise, and stronger ability to fund high-cost biologics and innovative oral therapies. Within the G7, market access still differs by payer model, with the United States emphasizing commercial and public coverage dynamics and European members relying on national value assessments and negotiated pricing.

The European Union is central to the treatment landscape because centralized marketing authorization can support multi-country entry, while reimbursement remains nationally determined. BRICS countries offer long-term growth potential due to large populations and expanding specialty care, but PNH diagnosis rates and access to complement inhibitors vary significantly across Brazil, Russia, India, China, and South Africa. ASEAN markets are increasingly relevant as tertiary hospitals improve hematology capabilities, although affordability, laboratory access, and reimbursement remain key barriers to wider adoption.

GCC countries are important for premium specialty medicine adoption because several health systems prioritize advanced hospital infrastructure, rare disease programs, and international treatment standards. NATO membership is not a healthcare market structure, but many NATO countries overlap with high-income North American and European systems where regulatory alignment, resilient supply chains, cross-border clinical collaboration, and public health security considerations can influence biologics availability.

Key Country Insights Across Major PNH Treatment Markets

The United States is the primary innovation and commercialization hub for PNH treatment, supported by FDA orphan drug pathways, leading academic hematology centers, and rapid adoption of approved complement inhibitors. Canada follows a more centralized evidence review and provincial reimbursement model. Mexico and Brazil show rising demand for rare disease care, but treatment access often depends on public-sector coverage, litigation pathways, private insurance, and specialist-center availability.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have strong diagnostic and treatment infrastructure, although pricing, reimbursement, and prescribing criteria differ. Germany often provides earlier post-authorization access within its reimbursement framework, while France, Italy, Spain, and the United Kingdom rely on structured health technology assessment and budget impact review. Russia has specialist expertise in major cities, but access can be constrained by procurement, reimbursement variability, and regional differences in specialty care delivery.

China is expanding rare disease policy support and domestic innovation capacity, making it a major long-term growth market. Japan has a mature rare disease reimbursement environment and high clinical adoption of approved therapies. South Korea and Australia maintain advanced hematology care and regulatory systems aligned with evidence-based access. India has significant unmet need because of large population scale, underdiagnosis, affordability constraints, and uneven access to high-cost complement inhibitors.

Actionable Recommendations for PNH Treatment Leaders

Industry leaders should prioritize differentiated evidence that reflects how hematologists and payers evaluate modern PNH treatment: sustained hemolysis control, hemoglobin improvement, transfusion independence, reduction in breakthrough hemolysis, patient-reported fatigue improvement, safety, and adherence. Head-to-head and real-world evidence will become increasingly important as multiple therapies compete across C5, C3, factor B, and factor D mechanisms.

Organizations should also invest in diagnosis acceleration, including physician education, laboratory partnerships, and AI-enabled case-finding tools that route suspected patients to confirmatory flow cytometry. Market access teams need country-specific value dossiers that address rare disease budget impact, long-term outcomes, vaccination and infection risk management, administration costs, and quality-of-life gains. Patient support programs should be designed around adherence, home administration training, oral therapy persistence, and rapid management of breakthrough symptoms.

Research Methodology for Verified PNH Treatment Insights

This executive summary is based on a structured secondary research methodology using verified sources such as regulatory approvals and prescribing information from recognized medicines agencies, peer-reviewed hematology literature, clinical guideline statements, clinical trial publications, rare disease registries, and health technology assessment materials. The analysis emphasizes validated clinical and regulatory facts rather than unsubstantiated market estimates.

The research approach included therapy landscape mapping by mechanism of action, review of regional access conditions, assessment of reimbursement and policy environments, evaluation of innovation trends, and synthesis of evidence on unmet needs in PNH care. Insights were triangulated across regulatory, clinical, payer, and real-world evidence sources to support an SEO-ready market perspective for stakeholders in pharmaceutical strategy, diagnostics, commercialization, and healthcare investment.

Conclusion: The Future of PNH Treatment

The paroxysmal nocturnal hemoglobinuria treatment landscape is entering a more competitive and patient-centered phase. Established C5 inhibitors continue to play a central role, while proximal complement inhibitors and oral therapies are expanding the definition of optimal disease control. The landscape is increasingly shaped by convenience, durability, residual anemia management, real-world outcomes, and payer confidence in long-term value.

Future leadership will depend on evidence generation, earlier diagnosis, equitable access, and safe integration of digital and AI-enabled tools. Stakeholders that align clinical differentiation with regional reimbursement realities, robust safety management, and patient needs will be best positioned to advance outcomes in this high-value rare disease treatment landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Treatment Class

  • 7.1. Complement Inhibitors
    • 7.1.1. Eculizumab
    • 7.1.2. Ravulizumab
  • 7.2. Therapy
  • 7.3. Supportive & Preventive Care
    • 7.3.1. Blood Transfusion
    • 7.3.2. Iron Chelation Therapy
    • 7.3.3. Anticoagulation
    • 7.3.4. Iron & Folic Acid Supplementation

8. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Route of Administration

  • 8.1. Intravenous
  • 8.2. Subcutaneous
  • 8.3. Oral Administration

9. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Line of Therapy

  • 9.1. First Line
  • 9.2. Second Line
  • 9.3. Third Line

10. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Dosing Pattern

  • 10.1. Standard Interval Parenteral
  • 10.2. Extended Interval Parenteral
  • 10.3. Daily Oral Maintenance

11. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by End Use

  • 11.1. Hospitals
  • 11.2. Specialty Clinics / Hematology Centers
  • 11.3. Homecare Settings

12. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AstraZeneca PLC
  • 17.2. Alnylam Pharmaceuticals, Inc.
  • 17.3. Samsung Bioepis Co., Ltd.
  • 17.4. Novo Nordisk A/S
  • 17.5. Apellis Pharmaceuticals, Inc.
  • 17.6. Novartis AG
  • 17.7. F. Hoffmann-La Roche Ltd.
  • 17.8. Regeneron Pharmaceuticals, Inc.
  • 17.9. Chugai Pharmaceutical Co., Ltd.
  • 17.10. Akari Therapeutics, Plc
  • 17.11. Amgen Inc.
  • 17.12. BioCryst Pharmaceuticals, Inc.
  • 17.13. Kira Pharmaceuticals, Inc.
  • 17.14. NovelMed Therapeutics, Inc.
  • 17.15. Sanofi S.A.
  • 17.16. Swedish Orphan Biovitrum AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ECULIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ECULIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RAVULIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RAVULIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RAVULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SUPPORTIVE & PREVENTIVE CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SUPPORTIVE & PREVENTIVE CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SUPPORTIVE & PREVENTIVE CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD TRANSFUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD TRANSFUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD TRANSFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IRON CHELATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IRON CHELATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IRON CHELATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTICOAGULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTICOAGULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTICOAGULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IRON & FOLIC ACID SUPPLEMENTATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IRON & FOLIC ACID SUPPLEMENTATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IRON & FOLIC ACID SUPPLEMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL ADMINISTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL ADMINISTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL ADMINISTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL THIRD LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL THIRD LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL THIRD LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL STANDARD INTERVAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL STANDARD INTERVAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL STANDARD INTERVAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL EXTENDED INTERVAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL EXTENDED INTERVAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL EXTENDED INTERVAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DAILY ORAL MAINTENANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DAILY ORAL MAINTENANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DAILY ORAL MAINTENANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SPECIALTY CLINICS / HEMATOLOGY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SPECIALTY CLINICS / HEMATOLOGY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SPECIALTY CLINICS / HEMATOLOGY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 145. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 146. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 149. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 150. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 171. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 172. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 173. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 176. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 177. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 181. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 182. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 185. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 186. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 199. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 200. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 201. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 204. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 205. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 208. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 209. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 210. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 213. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 214. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 217. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 218. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 219. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 222. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 223. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 236. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 237. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 240. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 241. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 244. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 245. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 246. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 249. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 250. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. RUSSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. RUSSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 253. RUSSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 254. RUSSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 255. RUSSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. RUSSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. RUSSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 258. RUSSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 259. RUSSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. ITALY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. ITALY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 262. ITALY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 263. ITALY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 264. ITALY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. ITALY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. ITALY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 267. ITALY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 268. ITALY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. SPAIN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. SPAIN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 271. SPAIN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 272. SPAIN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 273. SPAIN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. SPAIN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 275. SPAIN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 276. SPAIN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 277. SPAIN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. INDIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. INDIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
  • TABLE 289. INDIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 290. INDIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2018-2032 (USD MILLIO